FDA Lifts Clinical Hold On Dynavax's Hep B Vaccine Heplisav, Limits Population
This article was originally published in Pharmaceutical Approvals Monthly
FDA has lifted the clinical hold on development of Dynavax's Hepatitis B vaccine Heplisav, allowing the firm to proceed with Phase III development - but in a smaller market than originally proposed: patients with chronic kidney disease
You may also be interested in...
GlaxoSmithKline's two-year delay to do more safety work on the vaccine and specifically on the AS04 adjuvant gets the sponsor past one major milestone with a strong vote on safety for use in girls and young women.
Pending further data on adjuvants from firms and NIH, FDA's Vaccines and Related Biological Products Advisory Committee is comfortable with FDA's plans to license unadjuvanted H1N1 flu vaccines under the strain change process.
Regulators offer option to proceed with the hepatitis B vaccine in kidney disease patients, but can the company bear the risk/cost burden of going it alone until it can repartner?